Drug development is a long marathon, and in vitro efficacy evaluation is the critical checkpoint on the path from candidate molecule to clinic. Relying on its three core technology platforms — immunobiology, cell biology, and molecular biology — Sailybio provides one-stop in vitro efficacy evaluation services spanning antibody drugs, cell therapies, and small-molecule drugs, accelerating your drug development process.
The Sailybio in vitro efficacy platform covers antibody efficacy assessment, cell function testing, molecular-level analysis, neutrophil research, and cell induction and expansion. We offer a wide range of standard assays and support customized experimental protocols.
In Vitro Efficacy Evaluation of Antibody Drugs
▸ ADCC assay
▸ ADCP assay
▸ Cell depletion assay
▸ SLE cell depletion assay
▸ CRS assay
▸ Neutrophil-mediated ADCC assay
Cell Binding and Functional Assays
▸ FACS Binding assay (cellular level)
▸ MLR assay
▸ T cell function assay
▸ Neutrophil binding assay
▸ Affinity assay with human immune cells
Molecular-Level Assays
▸ Multiplex cytokine assay
▸ Annexin V/PI apoptosis assay
▸ Serum stability assay
▸ Cell marker expression assay
Neutrophil Assessment
▸ Neutrophil reactive oxygen species (ROS) assay
▸ Neutrophil migration assay
Other Specialized Assays
▸ KIR testing services
▸ Cell irradiation services
▸ Customized cell isolation services
Cell Induction and Functional Validation
▸ T cell activation assay
▸ Treg cell expansion and functional validation services
▸ Dendritic cell (iDC/mDC) induction services
▸ Macrophage induction services
▸ NK cell activation and expansion services
▸ γδT cell activation and expansion services
Sailybio is equipped with a BSL-2 pathogenic microorganism laboratory and professional laboratory facilities that meet industry standards. The company has obtained GB/T 19001-2016 / ISO 9001:2015 quality management system certification and holds 70+ patents, safeguarding the reliability of every piece of experimental data.
From compliance approval to data delivery, Sailybio has built a system of six core strengths.
STEP 01 📜 Compliance Approval
Compliance approval is conducted in accordance with GCP regulations. Documentation meets the requirements for new drug applications, laying the foundation for IND/NDA submissions.
STEP 02 👥 Sample Matching
A rich Donor bank allows pre-screening of donors with better immune responses. Multiple immune cell subtypes are continuously updated, ensuring stable recall and rapid response.
STEP 03 🏭 Platform Operation
Three technology platforms work in concert, covering a full suite of in vitro efficacy evaluation systems including ADCC/ADCP/MLR/cell killing/multiplex cytokine assays.
STEP 04 🧪 Experimental Execution
Stable, standardized processes reduce variability in experimental conclusions. We have overcome challenges with highly unstable cells such as neutrophils, and offer 24-hour expedited service for urgent projects.
STEP 05 ✅ Quality Control Review
Every batch is strictly controlled, with full-process QC data traceability.
STEP 06 📊 Data Delivery
A 99% on-time delivery rate, meeting the compliance data requirements for new drug applications and accelerating our clients' development pipelines.
Case Study 1: Neutrophil-Based Reactive Oxygen Species Assay
🔬 Experimental Principle
▸ Under certain activating stimuli, neutrophils generate reactive oxygen species (ROS), and excessive ROS causes significant damage to the body.
🧪 Experimental Method
▸ Cells are labeled with the DCFH-DA fluorescent probe, and changes in cellular fluorescence intensity are measured to analyze the effect of a drug on neutrophil ROS production.
Case Study 2: Antibody-Mediated Cytotoxicity Assay — ADCC
🎯 Experimental Value
▸ The ability to produce an ADCC effect on target cells is an important functional indicator for antibody candidates targeting cancer-associated antigens.
▸ In the development of novel antibodies targeting TAAs or non-TAAs, the ADCC assay is widely regarded by the industry as a necessary method to validate or rule out the in vitro ADCC function of antibody candidates.
⚡ Experimental Advantages
▸ A stable, compliant source of immune cells shortens the experimental cycle and ensures consistency of conclusions.
▸ Based on a donor population of 2000+, NK cell donors with better immune responses can be pre-screened, accelerating development and reducing R&D costs.
📊 Typical Data
▸ The drug Herceptin shows a pronounced ADCC effect on Her2-high tumor cells, in a dose-dependent manner.
▸ PBMC effector cells from different Donor sources show markedly different killing effects.
Case Study 3: γδT Cell Activation and Expansion
⚡ Experimental Advantages
▸ We provide stable and reliable γδT cell activation and expansion services. After 12 days of activation, γδT cells can expand more than 400-fold, with purity reaching over 91%.
▸ After 12 days of activation and expansion, γδT cells co-incubated with K562 cells at various ratios all produce pronounced killing effects on K562 cells, in a dose-dependent manner.
📊 Typical Data
